Bms-986466

Other Medications

EU Experimental ES med_spain_not_available 1 Clinical Trials

Description

Bms-986466 is an investigational drug, meaning it is still being studied in clinical trials and is not yet approved for treating any condition, including colorectal cancer (CRC). It was tested in a Phase 1 clinical trial (NCT06024174) for patients with advanced solid tumors that have a specific mutation called KRAS G12C. This trial included patients with CRC, as well as other cancers like lung, pancreatic, and biliary tract cancers. The trial aimed to determine a safe dose of Bms-986466, often given in combination with other drugs (adagrasib, sometimes with cetuximab), and to see if the combination was effective. The trial has been terminated. Bms-986466 is taken orally (by mouth).

Mechanism of Action

Bms-986466 is being studied as a potential treatment for cancers with the KRAS G12C mutation. The specific way it works (its molecular target or mechanism of action) is not fully detailed in the available trial information, but it is designed to target cancer cells. It was often studied in combination with adagrasib, which targets the KRAS G12C protein directly, and sometimes with cetuximab, which targets the EGFR protein. The trial aimed to evaluate the safety and effectiveness of Bms-986466 in this setting.

Side Effects

As Bms-986466 is an investigational drug and the clinical trial (NCT06024174) has been terminated Specific side effect data related to its use in CRC patients is limited. Side effects observed in Phase 1 trials can vary widely and are primarily related to determining safe dosages. Common side effects in cancer trials can include fatigue Nausea Diarrhea And changes in blood counts But the specific side effect profile for Bms-986466 is still being evaluated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06024174 med_phase_prefix1
Archived
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
United States, Australia, Finland, France, Israel

Quick Info

CategoryOther Medications
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.